Columbia Income Builder Fund Institutional Class returned 1.83% in Q4 2025, outperforming its benchmark. Read the full ...
With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO ...
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...
Viatris (VTRS) targets 5–6% revenue and 9–10% EPS CAGR through 2030, backed by launches, pipeline and $11B M&A cash. Click here to read my most recent analysis.
The annual event drew a record-breaking 477 attendees from 250 companies and 20 countries to Kiawah Island, SC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results